Gong, Xiaohua
Chen, Xuejun
Kuligowski, Michael E.
Liu, Xing
Liu, Xiang
Cimino, Evan
McGee, Ryan
Yeleswaram, Swamy
Clinical trials referenced in this document:
Documents that mention this clinical trial
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
https://doi.org/10.1007/s40257-021-00610-x
Documents that mention this clinical trial
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
https://doi.org/10.1007/s40257-021-00610-x
Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies
https://doi.org/10.1007/s40257-022-00734-8
Documents that mention this clinical trial
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
https://doi.org/10.1007/s40257-021-00610-x
Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies
https://doi.org/10.1007/s40257-022-00734-8
Funding for this research was provided by:
Incyte Corporation
Article History
Accepted: 6 May 2021
First Online: 12 May 2021
Declarations
:
: The study was funded by Incyte Corporation, Wilmington, DE, USA.
: All authors are employees and shareholders of Incyte Corporation.
: The phase II and phase III study protocols were approved by the independent ethics committee or institutional review board at each study site, and the studies were conducted in accordance with the ethical principles of the Declaration of Helsinki, International Council for Harmonization E6 Good Clinical Practice consolidated guidelines, and all applicable local laws/regulations.
: All patients provided written informed consent before initiating treatment.
: Not applicable.
: Incyte Corporation (Wilmington, DE, USA) is committed to data sharing that advances science and medicine while protecting patient privacy. Qualified external scientific researchers may request anonymized datasets owned by Incyte for the purpose of conducting legitimate scientific research. Researchers may request anonymized datasets from any interventional study (except phase I studies) for which the product and indication have been approved on or after 1 January 2020 in at least one major market (e.g., US, EU, JPN). Data will be available for request after the primary publication or 2 years after the study has ended. Information on Incyte’s clinical trial data sharing policy and instructions for submitting clinical trial data requests are available at: ExternalRef removed.
: Not applicable.
: Xiaohua Gong, Xuejun Chen, Michael E. Kuligowski, and Swamy Yeleswaram were involved in the conception/design of the work. Michael E. Kuligowski, Evan Cimino, and Ryan McGee acquired the data. Xiaohua Gong, Xing Liu, and Xiang Liu analyzed the data. All authors drafted the manuscript or revised it critically for important intellectual content, and approved the manuscript.